LAS VEGAS, June 25, 2014 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company"), announced today the launch of a new service offering for the isolation and expansion of mesenchymal stem cells through its wholly owned subsidiary CorCell Companies, Inc. (CorCell). This service was researched and developed in CorCell's laboratory and offers expecting parents an additional stem cell banking option.

Joseph Vicente, President of Cord Blood America, Inc. commented, "It was just over a year ago when we announced our launch into the storage of cord tissue, our first product/service extension in company history from our core umbilical cord blood offering. In subsequent releases, we have commented about the success of this launch with approximately 60% of our customers choosing to store both cord blood and a segment of cord tissue. Today, I am excited to announce this newest extension of our service offering via the isolation and expansion of these mesenchymal stem cells."

Dr. Geoffrey O'Neill, Tissue Bank Director of CBAI added, "Since our entrance into the cord tissue market, CorCell has added a research and development component in our laboratory aimed at refining and validating our processes and services. From this research, we have successfully developed a process for isolating and expanding cord tissue derived mesenchymal stem cells, which can be more readily stored and re-grown as needed. Many clinical trials for degenerative diseases are currently underway using these cells, and the isolation of these stem cells provides a readily available resource should they be needed for future medical treatments. "

Cord Blood America, Inc. is the parent company of CorCell Companies, Inc. which, along with Cord Blood America, Inc., facilitates umbilical cord blood and cord tissue stem cell processing and storage for expectant parents and their children. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell Companies, Inc., visit our websites: http://www.cordblood-america.com/ for investor information and http://www.corcell.com/ for customer information.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.